Organon & Co. Plans Quarterly Dividend of $0.02 (NYSE:OGN)

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, February 12th. Stockholders of record on Monday, February 23rd will be paid a dividend of 0.02 per share on Thursday, March 12th. This represents a c) annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Monday, February 23rd.

Organon & Co. has a dividend payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.1%.

Organon & Co. Trading Down 7.9%

Shares of Organon & Co. stock opened at $7.08 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.20 and a debt-to-equity ratio of 9.69. The company has a fifty day simple moving average of $7.88 and a 200-day simple moving average of $8.61. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 3.69, a PEG ratio of 1.66 and a beta of 0.58. Organon & Co. has a 12-month low of $6.18 and a 12-month high of $17.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The business’s revenue was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.90 EPS. On average, equities analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on OGN. Zacks Research lowered Organon & Co. from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Barclays started coverage on shares of Organon & Co. in a research report on Tuesday, December 9th. They set an “underweight” rating and a $7.50 target price on the stock. Morgan Stanley reduced their price target on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 11th. Piper Sandler cut shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research note on Monday, October 27th. Finally, Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $8.38.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.